PAT-LM1 is a natural human antibody that has been shown to have anti-cancer properties, in multiple animal models, including a potent effect in models of pancreatic, lung and colon cancers.
The lead product binds to a proprietary disease target that is expressed on the surface of cancer cells, but not on the surface of the healthy tissues screened.
Patrys has filed patent applications to cover the PAT-LM1 molecule and its disease target.
Patrys has an existing arrangement with Laureate for the production of another lead anti-cancer product PAT-SM6, which is currently being evaluated in a human clinical trial targeting patients with melanoma.
Patrys Manufacturing VP Mike Conner said Laureate has extensive antibody production experience and given the success with PAT-SM6 production, which is very similar to what will be needed for PAT-LM1, the company is confident that Laureate can produce yields of PAT-LM1 sufficient to support commercialization.